Many preclinical decisions come down to one question: will a molecule reach its target at a tolerable dose and behave predictably enough to enter clinical testing? Drug metabolism and pharmacokinetics (DMPK) studies help teams answer that question.
Recent regulatory milestones have also clarified expectations. ICH M12, Drug Interaction Studies, reached Step 4 on May 21, 2024, establishing a harmonized approach to enzyme- and transporter-mediated interaction assessment.
FDA published the final ICH M12 guidance and a companion Questions and Answers document in August 2024, then finalized its guidance on human radiolabeled mass balance studies in September 2024. Together, these documents make the preclinical package easier to plan but harder to improvise.
Key Takeaways
- DMPK supports decisions, not just data collection. Early in vitro screening and in vivo pharmacokinetics inform chemistry, candidate selection, and first-in-human dose planning.
- Interaction risk now follows a harmonized process. ICH M12 connects in vitro inhibition and induction findings with clinical study choices across regions.
- Bioanalytical quality affects whether data withstand review. ICH M10, adopted in May 2022, sets accuracy and precision criteria for mass spectrometry and ligand-binding methods.
- Provider selection should reflect program milestones. Teams should compare assay panels, species coverage, radiolabel capabilities, and turnaround against the studies they need next.
What DMPK Covers
ADME refers to four processes: absorption, distribution, metabolism, and excretion. Pharmacokinetics describes the resulting concentration of a compound and its metabolites in the body over time. DMPK connects the two by using mechanistic ADME data to explain and predict exposure.
Discovery work usually starts with a focused in vitro panel covering solubility, permeability, metabolic stability in liver microsomes or hepatocytes, and plasma protein binding. Rodent pharmacokinetic studies then estimate clearance, half-life, volume of distribution, and oral bioavailability. The comparative results help medicinal chemists understand why one compound achieves better exposure than another and which structural changes may improve the series.
Mapping Studies to IND-Enabling Milestones
A practical study plan is organized by development stage rather than by assay catalog.
- Hit-to-lead: Higher-throughput ADME screening for permeability, protein binding, and metabolic stability, followed by limited pharmacokinetic studies on representative compounds.
- Lead optimization: Reactive metabolite and time-dependent inhibition assessment, cross-species metabolism comparisons, and transporter substrate screens that anticipate distribution and clearance questions.
- IND-enabling: A structured interaction risk assessment aligned with ICH M12, planning for clinical index drug studies, physiologically based pharmacokinetic modeling when justified, and early scoping of a radiolabeled mass balance study.
Few small teams can staff every capability internally. For groups moving toward an IND, a provider of ADME DMPK services can place in vitro screens, in vivo pharmacokinetics, transporter studies, interaction assessments, and bioanalysis on one timeline. This may reduce sample handoffs and inconsistent methods across laboratories. Viva Biotech is one contract research organization that offers this type of consolidated DMPK support. Whether the model fits depends on the program’s modality, species requirements, schedule, and remaining method-development needs.
Assessing Interaction Risk Under ICH M12
ICH M12 formalizes a familiar process: characterize inhibition and induction potential in vitro, then determine which clinical studies will provide useful evidence. Enzyme studies assess reversible inhibition, time-dependent inhibition, and induction. Transporter studies examine whether the compound is a substrate, an inhibitor, or both.
Two reference points help teams define the scope. FDA describes sensitive index substrates as drugs whose area under the concentration-time curve increases fivefold or more when they are administered with strong inhibitors. These compounds therefore play an important role in clinical interaction study designs.
FDA also recommends in vitro inhibition testing for transporters such as P-glycoprotein, BCRP, OATP1B1, OATP1B3, OCT2, MATE1, MATE2-K, OAT1, and OAT3. For intestinal efflux transporters, an Igut/IC50 ratio of 10 or more indicates potential in vivo inhibition of P-glycoprotein or BCRP and may warrant follow-up.
Interaction gaps can be costly when they emerge late. A missing transporter assay may not block an IND by itself, but it can lead to additional work or a study amendment during review.
Planning a Human Mass Balance Study
FDA’s final guidance on clinical pharmacology considerations for human radiolabeled mass balance studies, issued in September 2024, clarifies when absorption, metabolism, and excretion studies are appropriate. It also addresses how sponsors should design and report them for investigational drugs.
A mass balance study answers questions that no in vitro system can fully resolve: how much of a dose is recovered, which routes eliminate it, and which circulating metabolites may be clinically important. If exposure to a metabolite is substantially higher in humans than in toxicology species, additional safety assessment may be necessary. Radiolabel synthesis, dosimetry, and site logistics can take time, so early scoping helps prevent delays later in development.
Meeting the Bioanalytical Standard in ICH M10
Every pharmacokinetic conclusion depends on the assay used to generate the concentration data. ICH M10, adopted in May 2022, sets validation expectations that sponsors and contract research organizations should agree on before samples are analyzed.
For chromatographic methods such as LC-MS/MS, accuracy should generally remain within plus or minus 15 percent, and precision should be 15 percent or better. At the lower limit of quantification, both thresholds relax to 20 percent. For ligand-binding assays, ICH M10 generally allows 20 percent for accuracy and precision and 25 percent at the lower and upper limits of quantification.
These criteria require practical controls, including adequate quality-control levels across the calibration range, documented carryover checks, dilution integrity for high-concentration samples, and stability data that reflect actual storage conditions. A well-developed bioanalytical method reduces the risk of repeating studies or questioning pivotal results.
Using Models to Inform Planning
Physiologically based pharmacokinetic models connect preclinical findings with possible clinical outcomes. They can simulate transporter-mediated interactions, the effect of gastric pH changes on a weakly basic compound, or exposure in populations that are difficult to study directly. A well-qualified model may also inform whether an additional clinical study is needed. Its credibility, however, still depends on reliable in vitro and pharmacokinetic inputs and clearly stated assumptions.
Choosing a Provider
Provider discussions should focus on what the next milestone requires:
- Experience with the relevant modality, including small molecules, antibody-drug conjugates, degraders, or oligonucleotides.
- Enzyme and transporter panels that cover the program’s ICH M12 assessment.
- Radiolabeled capabilities, including quantitative whole-body autoradiography and support for human mass balance studies.
- Bioanalytical methods aligned with ICH M10 and capacity to develop assays for difficult matrices.
- Appropriate species coverage, practical sample logistics, and realistic turnaround commitments.
Published capabilities provide a starting point for comparison, but they should be confirmed during study planning. Viva Biotech reports high-throughput in vitro ADME capacity, pharmacokinetic and blood-brain barrier studies, and work across five preclinical species.
That combination may make Viva Biotech suitable for programs that need volume screening alongside central nervous system exposure studies. Charles River describes a large, distributed ADME team, while WuXi AppTec emphasizes rapid screening and integrated IND-enabling packages.
QPS highlights radiolabeled ADME capabilities and centralized DMPK laboratories in Newark, Delaware. These profiles serve different needs, so teams should compare scientific fit, data quality, communication, and scheduling rather than relying on scale alone.
Sequencing Studies and Avoiding Common Pitfalls
Parallel work can shorten the critical path. Transporter and time-dependent inhibition assays can run alongside in vivo pharmacokinetic studies. Development of the regulated bioanalytical method can begin before toxicology samples are collected. Radiolabel production and dosimetry planning can also start while candidate selection is being completed.
Two problems recur. The first is a discovery bioanalytical method that was never validated to ICH M10 standards, with the gap discovered only after pivotal samples have been collected. The second is an interaction package with narrower transporter coverage than ICH M12 anticipates. Both problems are easier and less costly to prevent in the study plan than to address in response to regulatory questions.
Bringing It Together
Aligning preclinical DMPK work with current guidance turns separate assays into a defensible explanation of human exposure and safety. ICH M12 frames the interaction assessment, the September 2024 mass balance guidance shapes the disposition strategy, and ICH M10 sets the measurement standard. Model-informed methods can then connect those data with dose selection. Teams that define each milestone against the relevant guidance and select providers based on capability fit are less likely to repeat studies or revisit decisions late in development.
